Premium
Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: The influence of neoadjuvant treatment
Author(s) -
Kawata Nozomu,
Yagasaki Hiroki,
Yuge Humikazu,
Nakanoya Yuji,
Fujimura Kei,
Sugimoto Shuji,
Hirakata Hitoshi,
Takimoto Yukie
Publication year - 2001
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1046/j.1442-2042.2001.00299.x
Subject(s) - medicine , renal cell carcinoma , oncology , carcinoma , neoadjuvant therapy , cancer research , pathology , cancer , breast cancer
Background: This study was conducted in order to clarify whether histopathologic analysis of factor thymidine phosphorylase (TP) and Factor VIII could be a useful predictor of postoperative recurrence in localized renal cell carcinoma. Therefore, the relationship between tumor infiltrated lymphocytes (TIL) and both TP and Factor VIII was studied. Method: Of the 71 patients who underwent surgery, 54 patients had no neoadjuvant therapy (group 1), 10 patients were preoperatively administered IFN‐γ (group 2), and the remaining seven patients preoperatively received IFN‐γ and transarterial embolization (group 3). Both TP and Factor VIII immunostaining were performed on formalin‐fixed, paraffin‐embedded archival tissue from 71 renal cell carcinoma specimens, while TIL immunostaining was performed on frozen sections. Positive immunostaining was quantitatively scored by a computer‐assisted digital image analysis. For TIL, positive results were semiquantitatively scored. Results: A significant difference in the recurrence‐free rate was recognized for Groups 1, 2 and 3 ( P < 0.05). Therefore, the median TP‐positive rate (PR), VIII‐PR, number of microvessels and positive mean vascular area levels were investigated, between the recurrence cases ( n = 6) and the recurrence‐free cases ( n = 11). Only the TP‐PR levels showed a significant difference among them ( P = 0.044). In regards to the neoadjuvant cases, a significant correlation was observed between both VIII‐PR and CD4 ( r = 0.815) as well as between VIII‐PR and CD11b ( r = 0.756). Conclusion: There was no clear evidence that the neoadjuvant treatment would increase the recurrence‐free survival in patients with localized renal cell carcinoma. TP‐PR might be a predictor of postoperative recurrence in patients with localized renal cell carcinoma.